Equity Research
William Blair research analyst Andy Hsieh was quoted by Bloomberg following the recent earnings report from biopharma company Viking Therapeutics.
“While Viking’s drug must still undergo late-stage testing, the results exceeded expectations, indicating it may end up being more effective than Zepbound,” Hsieh’s note to investors that was quoted by the publication said.
Stay up-to-date with the latest William Blair news and insights
In this episode of William Blair Thinking Presents, macro analyst Richard de Chazal puts inflation and Fed rates under a microscope, explains the correlation between gold prices and bond yields, and discusses the Fed’s independence when it comes to policy changes during an election year.
Listen to the podcastWilliam Blair initiated research coverage of AAON, Inc. (AAON $89.90), a manufacturer of semi-custom and custom commercial HVAC systems.
Read moreWilliam Blair initiated research coverage of First Advantage Corporation (FA $15.32), a leading global provider of technology-enabled background screening products.
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
